Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey M Frankel

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Urology Practice|August 18, 2023
Editorial CommentaryJeffrey M Frankel
Urology Practice|April 27, 2023
Editorial CommentaryJeffrey M Frankel
Urology Practice|April 27, 2023
Editorial CommentJeffrey M Frankel
Urology Practice|January 12, 2024
Editorial CommentJeffrey M Frankel
Urology|June 18, 2013
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladderSender Herschorn, Jack Barkin, David Castro-Diaz, et al.
Blood Pressure Monitoring|March 27, 2018
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trialMichael A Weber, Christopher R Chapple, Christian Gratzke, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Urology Practice|August 18, 2023
Editorial CommentaryJeffrey M Frankel
Urology Practice|April 27, 2023
Editorial CommentaryJeffrey M Frankel
Urology Practice|April 27, 2023
Editorial CommentJeffrey M Frankel
Urology Practice|January 12, 2024
Editorial CommentJeffrey M Frankel
Urology|June 18, 2013
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladderSender Herschorn, Jack Barkin, David Castro-Diaz, et al.
Blood Pressure Monitoring|March 27, 2018
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trialMichael A Weber, Christopher R Chapple, Christian Gratzke, et al.
Pageof 1